PMV Pharmaceuticals

PMVP

Market cap $66.2M

Overview Fund Activity

1.25 USD

+0.05

4.17%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

1.28

+0.03

2.4%

1 day

4.17%

5 days

-3.1%

1 month

-19.87%

3 months

14.68%

6 months

-0.79%

Year to date

-18.3%

1 year

-16.67%

5 years

-96.67%

10 years

-96.67%

About: PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.

Employees: 47

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 55 [Q1] → 55 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

5.11% less ownership

Funds ownership: 71.87% [Q1] → 66.76% (-5.11%) [Q2]

10% less capital invested

Capital invested by funds: $40.7M [Q1] → $36.8M (-$3.92M) [Q2]

35% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 20

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $8K

See Fund Rankings

Financial journalist opinion

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

The Motley Fool

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Zacks Investment Research

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed or refractory AML/MDS harboring a TP53 Y220C mutation Cash, cash equivalents, and marketable securities of $183.3 million as of December 31, 2024 providing expected cash runway to end of 2026 PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology clinical-stage company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the full year ended December 31, 2024, and provided a corporate update.

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Zacks Investment Research

Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher

PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

See News Rankings

Charts implemented using Lightweight Charts™